SMS Pharmaceuticals credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
365365311280253
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
319319269244245
0.46×0.46×0.49×0.52×0.55×
0.41×0.41×0.42×0.45×0.53×
2.13×2.13×2.24×2.40×4.63×
1.85×1.86×1.94×2.09×4.50×
5.69×5.69×5.64×3.63×1.02×
31.7%31.7%32.7%34.3%35.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SMSPHARMA₹475.45

SMS Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABSOLARADCALUNICHEMLABGUFICBIORPGLIFEHIKALGUJTHEMMcap ₹4,453 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt252.5280.2310.8365.0365.0
Net Debt245.0244.0269.2319.0319.0
Total Debt/Equity0.550.520.490.460.46
Net Debt/Equity0.530.450.420.410.41
Total Debt/EBITDA4.632.402.242.132.13
Net Debt/EBITDA4.502.091.941.861.85
Interest Coverage (EBIT/Interest)1.023.635.645.695.69
Total Debt/Total Capital %35.4134.3132.7031.7231.72
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.